On January 20, 2015 Verastem reported on dosing of the first patient in a new clinical trial evaluating the combination of VS-5584, its dual mTORC1/2 and PI3K inhibitor, in combination with VS-6063, the Company’s lead focal adhesion kinase (FAK) inhibitor, in patients with relapsed mesothelioma (Press release Verastem, JAN 20, 2015, View Source;p=RssLanding&cat=news&id=2008677 [SID:1234501359]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Phase 1 open-label, dose escalation and schedule finding study is designed to assess safety, pharmacokinetics, pharmacodynamics and initial observations of clinical activity. The study is expected to enroll up to 56 patients at clinical sites in the UK and US.
"We are very pleased to initiate the first ever Phase 1 trial combining a dual mTORC1/2 and PI3K inhibitor (VS-5584) with a FAK inhibitor (VS-6063)," said Udai Banerji, MD, PhD, FRCP, Reader in Molecular Cancer Pharmacology and Honorary Consultant in Medical Oncology at The Royal Marsden Hospital and The Institute of Cancer Research London. "This study builds on robust synergy data from pre-clinical mesothelioma models presented by Verastem at the recent iMiG meeting. The trial is enrolling patients with relapsed mesothelioma: a patient population in dire need of new treatment options."
"Mesothelioma is a devastating disease and Verastem is committed to the development of new treatment options," said Dr. Joanna Horobin, Chief Medical Officer of Verastem. "This is the third study we have initiated with VS-6063 in patients with mesothelioma. We are very pleased with the progress of the multinational COMMAND study evaluating VS-6063 as a switch maintenance therapy following frontline chemotherapy in patients with malignant pleural mesothelioma. As reported in October at the 2014 iMIG, we are encouraged by the biomarker response and intriguing tumor shrinkage observed after 12 days of single agent VS-6063 administration in patients with untreated mesothelioma, prior to planned surgery. In this new study of VS-6063 in combination with VS-5584, building on the synergy seen in pre-clinical models, we hope to extend the potential benefit to patients with mesothelioma that has relapsed following initial therapy."
VS-5584 is currently in a Phase 1 study in advanced solid tumors where the compound has been generally well tolerated and preliminary activity has been observed, including in mesothelioma. Some patients have been on study for over 6 months and the maximum tolerated dose of VS-5584 has not been reached.
The combination clinical trial is supported by preclinical work demonstrating the synergistic activity of VS‐6063 and VS‐5584 in mesothelioma models in vitro and in vivo. In this preclinical research, the combination of VS‐6063 and VS‐5584 displayed synergistic reduction in cell viability based on multiple combination analysis models. When tested in vivo for reduction of mesothelioma tumor growth, VS‐6063 and VS‐5584 were each active as single agents and demonstrated synergistic antitumor efficacy when used in combination.